ArticleArthritis research & therapy2026
The inhibition of miR-125b-5P prevented Treg differentiation through activating STAT3/HIF-1α pathway in PBMCs of ankylosing spondylitis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAnkylosing spondylitis (AS) is a chronic inflammatory disease affecting the spine and joints. Its pathogenesis results from complex interactions among genetic, environmental, and immunological factors. Recent research has highlighted the role of regulatory T cells (Tregs) in maintaining immune homeostasis and suppressing excessive inflammation in AS. However, the mechanisms regulating Treg cell differentiation and function in AS remain poorly understood.
objectiveThis study aimed to elucidate the role of miR-125b-5p in regulating Treg cell differentiation and function in AS patients.
methodsPeripheral blood mononuclear cells (PBMCs) from AS patients and healthy controls (HC) were analyzed to investigate mechanisms underlying the Th17/Treg cell imbalance in AS. Flow cytometry, quantitative real-time PCR (qRT-PCR), Western blot, dual-luciferase reporter assay, enzyme-linked immunosorbent assay (ELISA), and co-immunoprecipitation (Co-IP) techniques were employed to assess the expression and regulatory functions of key molecules in Treg differentiation and function.
resultsThe proportion of Treg cells was significantly decreased in PBMCs from AS patients, with decreased expression of FOXP3, IL-2, and IL-10. Meanwhile, we found that STAT3 was ur-regulaed in AS-PBMCs; STAT3 overexpression suppressed FOXP3 expression, whereas STAT3 knockdown restored it. Then, the online databases (ENCORT, miRWalk, TargetScan, miRTarBase, miRcode) predicted that STAT3 mRNA could be interacted by miR-125b-5p, which regulated its expression. The dual-luciferase reporter assay further demonstrated that miR-125b-5p can directly interact with 3’-UTR of STAT3 mRNA, which repressing its expression. Interestingly, MiR-125b-5p was significantly downregulated in AS PBMCs. Overexpression of miR-125b-5p increased Treg cell frequency and enhanced IL-10 and TGF-β1 secretion through inhibiting STAT3/HIF-1α axis. Additionally, we also found that STAT3 could interact with NOX2 proteins. NOX2 overexpression modulated the STAT3/HIF-1α pathway, affecting Treg cell differentiation.
conclusionsMiR-125b-5p regulates Treg cell differentiation and function by regulating STAT3 expression in AS patients. Moreover, NOX2 also affects Treg differentiation through the STAT3/HIF-1α pathway. These findings suggest new potential targets for immunomodulatory therapy in AS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.